文献速递乳腺技术与安全MR

合成MRI定量映射用于识别乳腺癌受体状态、增殖率和分子亚型

Synthetic MRI with quantitative mappings for identifying receptor status, proliferation rate, and molecular subtypes of breast cancer.
PubMed 文献 · Eur J Radiol · 2022-01-20

本回顾性研究纳入2019年5月至2020年10月接受乳腺MR(含合成MRI)检查的可疑乳腺病变患者115例,获取病灶增强前后T1、T2、PD定量参数。T1、T2、PD及T2-Gd可作为鉴别受体状态和增殖率的影像生物标志物,T2和T2-Gd在分子亚型间有显著差异,T1和T2在三阴性癌与非三阴性癌间有显著差异。

要点

  • T2和T2-Gd在分子亚型间差异显著(P=0.000和P=0.006),可进一步区分Luminal A/B型与非Luminal型。
  • T1和T2在三阴性癌与非三阴性癌间差异显著(P=0.004和P=0.024)。
  • T1、T2、PD及T2-Gd可作为鉴别乳腺癌受体状态和增殖率的影像生物标志物。

核心结论

  • 合成MRI定量映射参数可能为无创鉴别乳腺癌患者受体状态、增殖率和分子亚型提供生物标志物。

研究设计与样本

  • 回顾性研究,纳入2019年5月至2020年10月符合纳入标准的115例可疑乳腺病变患者,行乳腺MR检查(含合成MRI),获取病灶增强前后T1、T2、PD定量参数。

关键影像表现/征象

  • Luminal A/B型肿瘤T2和T2-Gd值较低(分别为79.5 ms和68.00 ms),非Luminal型肿瘤较高(分别为84.00 ms和75.00 ms)。
  • 三阴性肿瘤T1和T2值较高(分别为1.54×10³ ms和84.00 ms),非三阴性肿瘤较低(分别为1.39×10³ ms和80.00 ms)。

诊断标准与关键数值

  • T2和T2-Gd在分子亚型间差异显著(P=0.000和P=0.006),可区分Luminal A/B型与非Luminal型(P=0.005和P=0.015)。
  • T1和T2在三阴性癌与非三阴性癌间差异显著(P=0.004和P=0.024)。
  • T1、T2、PD和T2-Gd可作为鉴别受体状态和增殖率的影像生物标志物。

临床应用与阅片要点

  • 合成MRI定量参数T2和T2-Gd可能有助于无创区分Luminal A/B型与非Luminal型乳腺癌。
  • T1和T2可能有助于无创区分三阴性癌与非三阴性癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate whether quantitative parameters of synthetic magnetic resonance imaging (MRI) can be used to differentiate among receptor status, proliferation rate, and molecular subtypes in patients with breast cancer.

MATERIALS AND METHODS: This retrospective study included patients with suspicious breast lesions who underwent breast MR examinations (including synthetic MRI) from May 2019 to Oct 2020. Quantitative parameters of synthetic MRI, including T1, T2, and proton density (PD) in the breast lesions before and after (T1-Gd, T2-Gd, and PD-Gd) contrast agent injection were obtained. The Wilcoxon rank sum was utilized to analyze the differences between the parameters and receptor status, proliferation rate, Luminal A/B, TN, and HER2-enriched. The Spearman's rank correlation test was used to analyze association between parameters among five molecular subtypes.

RESULTS: 115 patients who met the inclusion criteria were included. Quantitative T1, T2, PD, and T2-Gd can be used as imaging biomarkers for the different receptor status and proliferation rate of breast cancer. Among them, T2 and T2-Gd were significantly different in the molecular subtypes (P = 0.000 and P = 0.006, respectively) and can further differentiate luminal A/B breast cancers from non-luminal subtypes (P = 0.005 and P = 0.015, respectively). T1 and T2 were significantly different between triple negative (TN) and non-TN breast cancers (P = 0.004 and P = 0.024, respectively). T2 and T2-Gd values were lower for luminal A/B tumors (79.5 ms and 68.00 ms, respectively) and higher for non-luminal tumors (84.00 ms and 75.00 ms, respectively). T1 and T2 values were higher for TN tumors (1.54 × 103ms and 84.00 ms, respectively) and lower for non-TN tumors (1.39 × 103 ms and 80.00 ms, respectively).

CONCLUSION: Quantitative parameters derived from synthetic MRI mappings may provide a non-invasive biomarker for discriminating receptor status, proliferation rate, and molecular subtypes in patients with breast cancer.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Gao, Yang, Li, et al. Synthetic MRI with quantitative mappings for identifying receptor status, proliferation rate, and molecular subtypes of breast cancer. Eur J Radiol. 2022. PMID: 35078137. doi:10.1016/j.ejrad.2022.110168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。